Diagnostic Nuclear Medicine involves the administration of trace quantities of radiopharmaceuticals to diagnose functional abnormalities in body tissues. It involves invivo imaging, invivo non-imaging (e.g. Thyroid Uptake studies, GFR estimation by Plasma sampling), and in-vitro laboratory procedures (e.g. Radioimmunoassays.
The invivo imaging is broadly divided into Planar Imaging, Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET).